- In November 2020, Genentech, a member of the Roche Group, announced that the U.S. FDA approved a supplemental New Drug Application (sNDA) for Xofluza (baloxavir marboxil). This approval allows Xofluza to be used as a single-dose treatment to prevent influenza in individuals aged 12 and older after exposure to someone with the flu, making it the first such medicine approved for post-exposure prophylaxis
Frequently Asked Questions
The market is segmented based on Segmentation, By Type (NSAIDs (Nonsteroidal Anti-Inflammatory Drugs) and Dihydroergotamine), Application (Primary Pelvic Congestion Syndrome and Secondary Pelvic Congestion Syndrome) – Industry Trends and Forecast to 2031
.
The Global Pelvic Congestion Syndrome Market size was valued at USD 680.13 USD Million in 2023.
The Global Pelvic Congestion Syndrome Market is projected to grow at a CAGR of 6.56% during the forecast period of 2024 to 2031.
The market report covers data from the U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa.
